The Development of iron chelators for the treatment of cancer - Lovejoy, David;R Richardson, Des
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

This monograph describes the development of novel NT and DpT series aroylhydrazone and thiosemicarbazone iron chelators for the treatment of cancer. It neatly reviews the role of iron in cancer and the development of chelators for cancer treatment before describing the synthesis and biological activity of the NT and DpT series of chelators in both in-vitro and in-vivo models of cancer. The authors conclude that the DpT series, in particular, may be clinical potential in the treatment of cancer.

Andere Kunden interessierten sich auch für
Produktbeschreibung
This monograph describes the development of novel NT and DpT series aroylhydrazone and thiosemicarbazone iron chelators for the treatment of cancer. It neatly reviews the role of iron in cancer and the development of chelators for cancer treatment before describing the synthesis and biological activity of the NT and DpT series of chelators in both in-vitro and in-vivo models of cancer. The authors conclude that the DpT series, in particular, may be clinical potential in the treatment of cancer.
Autorenporträt
David Lovejoy is a biomedical chemist with a strong interest in iron-binding drugs (iron chelators). He also has broad research interests in iron and copper cellular metabolism and the roles of these metals in Human disease. He is a Cancer Institute NSW research fellow currently based at the University of Sydney, Australia.